On September 27, 2020, dongying city in shandong province of human resources and social security bureau according to the human resources and social security department issued by the "management method about print and distribute postdoctoral innovation practice base in shandong province notice (lu man word [2020] no. 91) of the relevant requirements, on a medical technology co., LTD. Shandong road, layer upon layer audit, screening, field trips, Determine our company to be the first batch of provincial post-doctoral innovation practice base filing units. Postdoctoral Innovation Practice Base is a provincial postdoctoral work platform for universities, research institutes, enterprises and institutions to jointly cultivate and use high-level scientific and technological and managerial talents, and promote the combination of industry, education and research. The establishment of ...

On August 4, 2020, the Development and Reform Commission of Dongying City announced the list of enterprise technology centers in Dongying City in 2020, and our company was successfully selected as "Enterprise Technology Center of Dongying City". In recent years, our company attaches great importance to enterprise science and technology innovation work, vigorously support technology innovation projects, accelerate the construction of enterprise technology center; At the same time, support and encourage employees to carry out scientific and technological research and development, patent application and other work, and strengthen the guidance for the construction of enterprise technology center in terms of operation mechanism, investment, talent introduction and training, industry-university-research cooperation and other aspects, so as to continuously improve the company's ...

    近日，山东省工业和信息化厅公布了2022年度山东省“瞪羚”企业名单，山东道合药业有限公司榜上有名。     入选瞪羚企业具有重要意义。各级政府都在积极出台瞪羚独角兽企业的培育扶持政策，申报成功的企业有机会在金融、资金、用地等各个层面享受精准政策扶持及优先扶持权。其次，入选由权威机构征集、发布“瞪羚”榜单，有助于提升企业的知名度和影响力，使企业更容易借力金融资本，实现产融结合，迅速做强做大。     入选瞪羚企业后，山东道合药业将会以新技术、新业态、新模式为支撑稳步进入高速成长期。公司在延伸成熟产业链的同时，着力培育发展面向未来的技术研发、中试转化、生产服务等服务链。充分利用科研服务平台，全面整合创新创业资源，提升医药科技创新水平。努力成为中小企业标杆和榜样，更好地引领区域经济发展。

利伐沙班 CAS:366789-02-8 靶点和IC50:  Factor Xa(0.7 nM),凝血酶原酶(2.1 nM) 原研公司：强生和拜耳 利伐沙班是拜耳公司和强生公司共同研发的一种高效FXa 抑制剂，用于髋或膝关节置换术后静脉血栓栓塞症(venous thromboembolism，VTE )的预防，有极好的体内活性和生物利用度。2008年10月1日分别在加拿大和欧盟获得上市批准。2009年3月获国家药监局批准上市。2011年7月1日获FDA批准，2012年1月18日获PMDA批准。利伐沙班化合物专利即将到期，价格面临雪崩。 作用机制 凝血因子 Xa是一种丝氨酸蛋白酶, 位于血液凝集级联的上游, 处在连接内源性和外源性激活途径共同通路的中心位置, 它既能阻断内源性凝血亦能抑制外源性凝血的发生。Xa因子是凝血酶生成的限速成分, 由于在血液凝集级联反应过程中还存在生物信号的放大, 估计一个 Xa因子抑制剂分子具有能抑制 138个凝血酶分子的生理效果, Xa因子抑制剂可能比凝血酶抑制剂更为有效 。本品是一个新合成的小分子, 能抑制活化的 FXa,&...

On July 1, dongying city Yang Mengbin, deputy director of the standing committee of National People's Congress standing committee members, director of the financial rong-hua xu on civil-operated departments and dongying port economic development zone management committee is responsible for the comrades, paid a visit to my company inspection, accompanied by the group President Yaopeng Wang, Mengbin Yang line visit the old and the new kinetic energy into major projects in shandong province. President Yaopeng Wang made a detailed report to Director Yang from the aspects of project planning, construction progress, project research and development, market prospect, difficulties and problems encountered by the company. Yang, director of our company in recent years the development of fully affirmed and highly evaluation, and encouraged me to strengthen the scientific research,...